The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 13, 2024

Filed:

Jul. 17, 2019
Applicant:

Manzanita Pharmaceuticals, Inc., Woodside, CA (US);

Inventors:

Stephen B. Kahl, Woodside, CA (US);

Constance A. McKee, Woodside, CA (US);

Assignee:

Manzanita Pharmaceuticals, Inc., Woodside, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/48 (2006.01); A61K 45/06 (2006.01); C07D 211/60 (2006.01); C07D 225/04 (2006.01); C07D 235/04 (2006.01); C07D 249/08 (2006.01); C07D 265/30 (2006.01);
U.S. Cl.
CPC ...
C07K 14/48 (2013.01); A61K 45/06 (2013.01); C07D 211/60 (2013.01); C07D 225/04 (2013.01); C07D 235/04 (2013.01); C07D 249/08 (2013.01); C07D 265/30 (2013.01);
Abstract

Conjugates for delivering an anti-cancer agent to nerve cells are provided. Conjugate compounds of the present disclosure according to certain embodiments include a compound having a protein, peptide or pepetidomimetic that binds selectively to a neurotrophin receptor, an anti-cancer agent and a linker that covalently bonds the anti-cancer agent to the protein, peptide or pepetidomimetic binds selectively to the neurotrophin receptor. Compositions and methods for delivering an anti-cancer agent selectively into nerve cells (e.g., in the treatment of optic pathway glioma) as well as indications such as perineural invasion and skin cancers are also described. Also provided are methods of making the anti-cancer conjugate compounds.


Find Patent Forward Citations

Loading…